Skip to main content
Jonathan M. Spergel on Muck Rack

Jonathan M. Spergel

As seen in: Allergy - European Journal of Allergy and Clinical Immunology, Color Research & Application, Wiley, Wiley Online Library, Pediatrics, Healio, FoodNavigator-USA, The Journal of Allergy & Clinical Immunology, Annals of Allergy, Asthma & Immunology, Clinical Gastroenterology and Hepatology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan M.

Contact Jonathan M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Eosinophilic esophagitis

|
By Jonathan M. Spergel
| Annals of Allergy, Asthma & Immunology Verified
A series of articles and editorials in this month’s issue highlights several new findings and information about eosinophilic esophagitis (EoE) which is a chronic disorder characterized by clinical symptoms of esophageal dysfunction and eosinophilic inflammation, defined as greater than 15 eosinophils per high power field.1-3 The pathophysiology of EoE is driven by a type 2 immune response, and uncontrolled disease causes esophageal remodeling and fibrosis.1-3 Despite the name, it is not...
Open in Who Shared Issue with article?

A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis

|
By Elaine Siegfried, Lara Lee, Jonathan M. Spergel, Randy Prescilla
| Wiley Online Library Verified
1 INTRODUCTION Dupilumab is a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, as an immunomodulator. Current regulatory labeling recommends completing all age-appropriate immunizations before initiating dupilumab treatment and avoiding live vaccine administration during treatment.1, 2 The LIBERTY AD PRESCHOOL (Part A and B; NCT03346434) study prohibited live attenuated vaccine administration within 4 weeks before the baseline visit and during treatment.
Open in Who Shared Issue with article?

Dupilumab improves type 2 comorbidity outcomes in patients with eosinophilic esophagitis and comorbid disease at baseline: from Parts A and B of LIBERTY-EoE-TREET

|
By Jonathan M. Spergel, Lawrence Sher, Sandy Durrani, Evan S. Dellon
| The Journal of Allergy & Clinical Immunology Verified
Dupilumab, a fully human mAb, blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation. In LIBERTY-EoE-TREET (NCT03633617) dupilumab improved histologic, symptomatic, and endoscopic aspects of EoE. This analysis evaluates the efficacy of dupilumab 300mg qw vs placebo on outcomes related to type 2 comorbidities in patients with EoE from Parts A and B of LIBERTY-EoE-TREET.
Open in Who Shared View Duplicates (1) Issue with article?
See all 63 licensed articles (64 Total)